DexCom (NasdaqGS:DXCM) reported that results from the CONNECT randomized controlled trial of its G7 CGM were published in The ...

(ISIN US2521311074) plans to release its third-quarter 2026 results on October 29, 2026, making the next earnings report the ...

DXCM's G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with ...

Continuous glucose monitors can dramatically improve blood sugar control among people with type 2 diabetes who aren’t yet ...

South Korea's CGM market reached 57.5 billion won in 2024, with imports holding 92.5% as Daewoong, Huons and i-SENS compete.

A wearable blood sugar monitor may help people with type 2 diabetes even when they don’t need insulin. In a newly published clinical trial, adults using the Dexcom G7 achieved significantly better ...

DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence. Read ...

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don ...

The benefits of wearable continuous glucose monitoring devices extend even to patients with diabetes who do not use insulin, ...

(This is an excerpt of Health Rounds, winner of the 2026 Publishers Newsletter Award for Best Science Newsletter, where we ...

Today we highlight a study that found benefits of wearable glucose monitoring devices for all patients with diabetes, ...